
The central government has approved capping the trade margin on all non-scheduled anti-cancer drugs at a maximum of 30% of the retail price, the PIB said on 8 October. The move could cut MRP on some drugs by 20% to 70% and save patients around Rs 2,500 crore each year. The order covers branded and generic, domestic and imported, and patented and non-patented drugs.
The National Pharmaceutical Pricing Authority (NPPA) found average markups on these drugs at 170%, with some cases exceeding 700%, the PIB said. The Director General of Health Services (DGHS) will form an expert committee to finalise the list of drugs to be covered, the committee is expected to submit its list by 14 October, TV9 Hindi reports. Manufacturers must maintain current production levels to ensure uninterrupted supply. A 2019 cap on 42 non-scheduled cancer drugs across 526 brands saved patients Rs 984 crore annually.
Update, 11 October 2026: Business Today on 10 October reports the chemicals and fertilisers ministry confirmed the 30% margin cap on non-scheduled cancer drugs, citing a Bloomberg report. The outlet states the NPPA will finalise the list of drugs covered, repeating the 70% price cut projection and Rs 2,500 crore annual saving estimate, without adding new facts beyond confirming the timeline.
The PIB and Amar Ujala carry the government's announcement as a straight affordability story, emphasising the 70% price cut projection and the 2,500 crore annual saving. TV9 Hindi adds two critical elements: the Supreme Court's earlier concern over a drug with a Rs 2,700 supply price and Rs 27,000 MRP, and civil society group WGAMT's questioning whether margin capping alone ensures affordability. Aaj Tak and Business Today stay neutral-report, reprinting the NPPA data and the DGHS timeline without extra framing. The coverage is uniform on the order itself, the divergence lies in whether the story is presented as a solved problem or an ongoing effort. The only concrete next step named is the DGHS expert committee's list due by 14 October.
Coverage: 6 sources, 1 pro-government, 1 government-critical, 4 neutral
Sources (6): amarujala.com (neutral report), tv9hindi.com (neutral report), pib.gov.in (pro government), aajtak.in (neutral report), tv9hindi.com (2) (government critical), businesstoday.in (neutral report)
This brief was synthesised by AI from the 6 sources linked above, so one read covers every framing they carry. Methodology and corrections.